Last reviewed · How we verify
PM02734 and erlotinib
PM02734 and erlotinib is a Small molecule drug developed by PharmaMar. It is currently in Phase 1 development.
At a glance
| Generic name | PM02734 and erlotinib |
|---|---|
| Sponsor | PharmaMar |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PM02734 and erlotinib CI brief — competitive landscape report
- PM02734 and erlotinib updates RSS · CI watch RSS
- PharmaMar portfolio CI
Frequently asked questions about PM02734 and erlotinib
What is PM02734 and erlotinib?
PM02734 and erlotinib is a Small molecule drug developed by PharmaMar.
Who makes PM02734 and erlotinib?
PM02734 and erlotinib is developed by PharmaMar (see full PharmaMar pipeline at /company/pharmamar).
What development phase is PM02734 and erlotinib in?
PM02734 and erlotinib is in Phase 1.
Related
- Manufacturer: PharmaMar — full pipeline
- Compare: PM02734 and erlotinib vs similar drugs
- Pricing: PM02734 and erlotinib cost, discount & access